221 related articles for article (PubMed ID: 32662546)
1. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients.
Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
Cancer Sci; 2020 Oct; 111(10):3893-3901. PubMed ID: 32662546
[TBL] [Abstract][Full Text] [Related]
2. Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing.
Su S; Zou JJ; Zeng YY; Cen WC; Zhou W; Liu Y; Su DH; Zhang XL; Huang HY; Lei A; Huang ZH; Jin Y; Li L; Su N; Xie YL; Zhao ZG; Liu JX
Biomed Res Int; 2019; 2019():6096350. PubMed ID: 31781628
[TBL] [Abstract][Full Text] [Related]
3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
4. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
[No Abstract] [Full Text] [Related]
5. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation.
Beca F; Sebastiao APM; Pareja F; Dessources K; Lozada JR; Geyer F; Selenica P; Zeizafoun N; Wen HY; Norton L; Brogi E; Weigelt B; Reis-Filho JS
Histopathology; 2020 Aug; 77(2):321-326. PubMed ID: 32043609
[TBL] [Abstract][Full Text] [Related]
9. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
11. Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients.
Nagashima T; Yamaguchi K; Urakami K; Shimoda Y; Ohnami S; Ohshima K; Tanabe T; Naruoka A; Kamada F; Serizawa M; Hatakeyama K; Matsumura K; Ohnami S; Maruyama K; Mochizuki T; Kusuhara M; Shiomi A; Ohde Y; Terashima M; Uesaka K; Onitsuka T; Nishimura S; Hirashima Y; Hayashi N; Kiyohara Y; Tsubosa Y; Katagiri H; Niwakawa M; Takahashi K; Kashiwagi H; Nakagawa M; Ishida Y; Sugino T; Takahashi M; Akiyama Y
Cancer Sci; 2020 Feb; 111(2):687-699. PubMed ID: 31863614
[TBL] [Abstract][Full Text] [Related]
12. Mutational concordance analysis provides supportive information for double cancer diagnosis.
Hatakeyama K; Nagashima T; Notsu A; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Kenmotsu H; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
BMC Cancer; 2021 Feb; 21(1):181. PubMed ID: 33607950
[TBL] [Abstract][Full Text] [Related]
13. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
14. Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds.
Alsaihati BA; Ho KL; Watson J; Feng Y; Wang T; Dobbin KK; Zhao S
Nat Commun; 2021 Aug; 12(1):4670. PubMed ID: 34344882
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K
Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191
[TBL] [Abstract][Full Text] [Related]
16. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
17. Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.
Raj SKS; Routh ED; Chou JW; Votanopoulos KI; Triozzi PL; Miller LD
Cancer; 2022 Sep; 128(17):3254-3264. PubMed ID: 35767280
[TBL] [Abstract][Full Text] [Related]
18. Mutational profiling of colorectal cancers with microsatellite instability.
Lin EI; Tseng LH; Gocke CD; Reil S; Le DT; Azad NS; Eshleman JR
Oncotarget; 2015 Dec; 6(39):42334-44. PubMed ID: 26517354
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
Siemers NO; Holloway JL; Chang H; Chasalow SD; Ross-MacDonald PB; Voliva CF; Szustakowski JD
PLoS One; 2017; 12(7):e0179726. PubMed ID: 28749946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]